Related Experiment Video

Updated: Jun 19, 2026

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Revisiting clinical trials on glycemic control and cardiovascular risk

Sandra Roberta Gouvea Ferreira1

  • 1Nutrition Department, School of Public Health, University of São Paulo, Brazil. sandrafv@usp.br.

Diabetology & Metabolic Syndrome
|October 15, 2009
PubMed

Insights

Strict glycemic control does not solely reduce cardiovascular risk in type 2 diabetes. Recent trials show mixed results, suggesting other factors are crucial for managing cardiovascular risk in long-term diabetes patients.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Examined clinical trials on glycemic control and cardiovascular risk reduction.
  • Highlighted the UK Prospective Diabetes Study (UKPDS) as a foundational trial.
  • Introduced controversial recent trials: ACCORD, ADVANCE, and VADT.

Discussion:

  • Discussed the controversy surrounding strict glycemic control (normal glycated hemoglobin).
  • Addressed the lack of conclusive evidence that strict control alone reduces cardiovascular risk.
  • Explored potential reasons behind the controversial findings in recent trials.

Key Insights:

  • Glycemic control alone is insufficient to mitigate cardiovascular risk in complicated, long-term type 2 diabetes mellitus.
  • Evidence from ACCORD, ADVANCE, and VADT challenges the universal benefit of intensive glucose lowering.
  • Individual patient factors likely play a significant role in cardiovascular outcomes.

Outlook:

  • Further research is needed to understand the multifactorial nature of cardiovascular risk in diabetes.
  • Exploring alternative or complementary strategies alongside glycemic control is essential.
  • Personalized treatment approaches may be necessary for optimizing cardiovascular outcomes in type 2 diabetes.

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...